Nanomedicine Drug Delivery Global Market Report 2025

The nanomedicine drug delivery market size has grown rapidly in recent years. It will grow from $106.51 billion in 2024 to $123.37 billion in 2025 at a compound annual growth rate (CAGR) of 15.8%. Growth during the historic period can be attributed to the increasing prevalence of chronic diseases, rising demand for targeted therapies, growing global healthcare expenditure, greater investment in pharmaceutical infrastructure, expansion of nanomedicine applications in oncology, and rising awareness of personalized treatment approaches.

The nanomedicine drug delivery market size is expected to see rapid growth in the next few years. It will grow to $219.3 billion in 2029 at a compound annual growth rate (CAGR) of 15.5%. The growth during the forecast period can be attributed to the rising global aging population, the increasing prevalence of cardiovascular and neurological disorders, the growing emphasis on precision medicine initiatives, the rise in government support for nanomedicine research, the development of healthcare infrastructure in emerging regions, and the strengthening collaborations between pharmaceutical and research organizations. Key trends in the forecast period include progress in nanoparticle-based drug carriers, improvements in stimuli-responsive nanocarriers, innovations in multifunctional nanomedicine platforms, advancements in nanoscale drug delivery for overcoming biological barriers, research and development in personalized nanotherapeutics, and progress in hybrid nanocarrier systems for controlled release.

The increasing adoption of personalized medicine is expected to drive the growth of the nanomedicine drug delivery market in the coming years. Personalized medicine refers to a medical approach that tailors treatment and prevention strategies to the unique characteristics of each patient, such as genetic profile or disease subtype. The adoption of personalized medicine is rising as advances in genomics and molecular science enable treatments customized to an individual’s genetic makeup, improving effectiveness and supporting precise, targeted care. Nanomedicine drug delivery complements personalized medicine by accurately directing drugs to target cells and adjusting dosages and formulations for each patient, improving therapeutic outcomes and minimizing side effects. For example, in February 2024, according to the Personalized Medicine Coalition, a United States-based international non-profit organization, the United States Food and Drug Administration approved sixteen new personalized treatments for patients with rare diseases in 2023, up from six approvals in 2022. Therefore, the increasing adoption of personalized medicine is propelling the growth of the nanomedicine drug delivery market.

Leading companies operating in the nanomedicine drug delivery market are focusing on developing advanced drug delivery solutions, such as AI-powered nano-delivery platforms, to enhance targeting precision and accelerate the development of personalized therapies. AI-powered nano-delivery platforms are advanced systems that use artificial intelligence to design and optimize nanoparticles for accurate drug targeting, improving therapeutic performance, minimizing adverse effects, and supporting individualized treatment approaches. For instance, in September 2025, METiS TechBio, a China-based biotechnology company, introduced NanoForge, an AI-driven nano-delivery platform aimed at transforming medicine development and delivery. The system combines artificial intelligence with nanotechnology to optimize lipid nanoparticle formulations and deliver drugs directly to target tissues, enabling faster, safer, and more cost-effective drug development. This innovation is designed to address major challenges in drug delivery for complex molecules such as mRNA, advancing the field toward programmable and adaptive therapeutics.

In July 2024, ME Therapeutics Inc., a Canada-based preclinical-stage immuno-oncology company, entered into a partnership with NanoVation Therapeutics Inc. to develop advanced messenger ribonucleic acid (mRNA) delivery systems aimed at targeting myeloid cells for cancer treatment. Through this collaboration, ME Therapeutics seeks to utilize NanoVation’s proprietary long-circulating lipid nanoparticle platform to improve the precision, efficacy, and in vivo targeting of mRNA therapeutics, accelerating the development of new treatments in the nanomedicine drug delivery sector. NanoVation Therapeutics Inc. is a Canada-based biotechnology company specializing in the design and development of lipid nanoparticle technologies for nucleic acid delivery.

Major players in the nanomedicine drug delivery market are Pfizer Inc., Bristol-Myers Squibb Company, Novartis AG, Gilead Sciences Inc., Evonik Industries AG, Ipsen Pharma S.A.S., Pacira BioSciences Inc., Camurus AB, Arcturus Therapeutics Holdings Inc., Nanobiotix S.A., Acuitas Therapeutics Inc., NanoViricides Inc., Taiwan Liposome Company Ltd., Aphios Corporation, Concept Medical Inc., DelSiTech Ltd., ANP Technologies Inc., ProMab Biotechnologies Inc., BlueWillow Biologics Inc., and Nanoform Finland Plc.

North America was the largest region in the nanomedicine drug delivery market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in nanomedicine drug delivery report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The nanomedicine drug delivery market research report is one of a series of new reports that provides nanomedicine drug delivery market statistics, including nanomedicine drug delivery industry global market size, regional shares, competitors with a nanomedicine drug delivery market share, detailed nanomedicine drug delivery market segments, market trends and opportunities, and any further data you may need to thrive in the nanomedicine drug delivery industry. The nanomedicine drug delivery market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Nanomedicine drug delivery involves the use of nanoscale materials and technologies to transport therapeutic agents directly to specific targets within the body. This approach enhances treatment precision and control, ensuring optimal interaction with disease sites. Nanomedicine drug delivery improves drug stability, absorption, and bioavailability, resulting in more effective therapeutic outcomes. Its key benefit is the reduction of systemic exposure while maximizing the therapeutic effect.

The primary product types of nanomedicine drug delivery include nanoparticles, liposomes, micelles, dendrimers, nanotubes, and others. Nanoparticles serve as nanoscale carriers that deliver therapeutic agents directly to targeted cells or tissues, improving drug efficacy and reducing side effects. These drug delivery systems can be administered through various routes such as oral, injectable, topical, and others. They are used in several therapeutic areas, including oncology, cardiovascular diseases, neurology, infectious diseases, and others, and are employed by end users such as hospitals, clinics, research institutes, and other healthcare facilities.

The countries covered in the nanomedicine drug delivery market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The nanomedicine drug delivery market consists of revenues earned by entities by providing services such as drug formulation services, nanocarrier design services, clinical trial management services, regulatory consulting services, contract research services, and contract manufacturing services. The market value includes the value of related goods sold by the service provider or included within the service offering. The nanomedicine drug delivery market also includes sales of nanocarrier-based drug formulations, targeted drug delivery systems, sustained release nanomedicines, polymeric nanoparticles, lipid-based nanocarriers, and nanoemulsions. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.